<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37661">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616250</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.105069</org_study_id>
    <nct_id>NCT02616250</nct_id>
  </id_info>
  <brief_title>MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM)
      associated with Brimonidine 0.33% gel (Br) compared with the association of their respective
      vehicles in the treatment of moderate to severe rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy variable: Percentage of patients across the 5 scores of the global rosacea severity grading scale called Investigator's Global Assessment (IGA).</measure>
    <time_frame>week 12</time_frame>
    <description>Percentage of patients across scores of IGA.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.
Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 0.33% gel (Br)</intervention_name>
    <arm_group_label>Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD07805/47 (Br) placebo gel</intervention_name>
    <arm_group_label>Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream</arm_group_label>
    <arm_group_label>CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 1% cream (IVM)</intervention_name>
    <arm_group_label>Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD5024 (IVM) placebo cream</intervention_name>
    <arm_group_label>CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male or female subjects age 18 years or older;

          2. Subjects with a minimum of 15 but not more than 70 inflammatory lesions (papules and
             pustules) of rosacea on the face;

          3. Subjects with moderate or severe diffuse persistent facial erythema of rosacea
             (scored 3 or 4 according to Clinician's Erythema Assessment [CEA]);

          4. Subjects with moderate or severe papulopustular rosacea (scored 3 or 4 according to
             the Investigator's Global Assessment [IGA]);

          5. Female subjects of childbearing potential with a negative urine pregnancy test (UPT);

          6. Female subjects of childbearing potential must practice a highly effective method of
             contraception during the study;

          7. Females subjects of non-childbearing potential;

        Main Exclusion Criteria:

          1. Subjects with particular forms of rosacea or other concomitant facial dermatoses that
             may be confounded with rosacea;

          2. Subjects with more than 2 nodules of rosacea on the face;

          3. Subjects with any uncontrolled chronic or serious disease or medical condition that
             may either interfere with the interpretation of the clinical trial results, or with
             optimal participation in the study or would present a significant risk to the
             subject;

          4. Subjects with known or suspected allergies or sensitivities to any component of the
             investigational and non-investigational products, including the active ingredients
             brimonidine or salts of brimonidine like brimonidine tartrate and ivermectin;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>November 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
